(Q37738532)

22 August 2017

1 reference

title

Eradicating minimal residual disease in chronic lymphocytic leukemia: should this be the goal of treatment? (English)

1 reference

eradication of infectious diseases

22 August 2017

0 references

1 reference

1 reference

chronic lymphocytic leukemia

1 reference

3

Peter Hillmen

0 references

Andy C Rawstron

object named as

Andy C Rawstron

series ordinal

2

0 references

author name string

Abraham M Varghese

series ordinal

1

1 reference

22 August 2017

publication date

1 January 2010

1 reference

22 August 2017

number of pages

10

1 reference

Current hematologic malignancy reports

inferred from page(s)

published in

1 reference

22 August 2017

volume

5

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

35-44

1 reference

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

22 August 2017

cites work

1 reference

12 December 2020

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

1 reference

12 December 2020

Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q- and 17p-)

1 reference

12 December 2020

In vivo 'Purging' of residual disease in CLL with Campath-1H

1 reference

12 December 2020

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

1 reference

12 December 2020

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

12 December 2020

High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia

1 reference

12 December 2020

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation

1 reference

12 December 2020

Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis

1 reference

12 December 2020

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

1 reference

12 December 2020

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

12 December 2020

Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial

1 reference

12 December 2020

Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.

1 reference

12 December 2020

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

12 December 2020

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia.

1 reference

12 December 2020

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.

1 reference

12 December 2020

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

1 reference

12 December 2020

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

12 December 2020

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

12 December 2020

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

1 reference

12 December 2020

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab

1 reference

12 December 2020

Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.

1 reference

12 December 2020

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population

1 reference

12 December 2020

Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses

1 reference

12 December 2020

Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia

1 reference

12 December 2020

The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia

1 reference

12 December 2020

Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication

1 reference

12 December 2020

Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia

1 reference

12 December 2020

Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia.

1 reference

12 December 2020

Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses

1 reference

12 December 2020

CHOP versus prednisolone + chlorambucil in chronic lymphocytic leukemia (CLL): preliminary results of a randomized multicenter study

1 reference

12 December 2020

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

1 reference

12 December 2020

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia

1 reference

12 December 2020

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

1 reference

12 December 2020

Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation

1 reference

12 December 2020

Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status.

1 reference

12 December 2020

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

1 reference

12 December 2020

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

1 reference

12 December 2020

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).

1 reference

12 December 2020

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

12 December 2020

10.1007/S11899-009-0041-2

Identifiers

DOI

1 reference

22 August 2017

1 reference